Education
About Us
Working with TipRanks
Follow Us
IQVIA Holdings Inc (IQV)
NYSE:IQV
IQV Stock Chart & Stats
$237.68
-$0.07(-0.03%)
At close: 4:00 PM EST
$237.68
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$134.65 - $247.05
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.23M
Market Cap
$41.09B
Enterprise Value$45.70B
Total Cash (Recent Filing)$1.97B
Total Debt (Recent Filing)$15.19B
Price to Earnings (P/E)32.6
Beta0.84
Next Earnings
Feb 18, 2026EPS Estimate
3.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding170,300,000
10 Day Avg. Volume1,191,237
30 Day Avg. Volume1,233,907
Financial Highlights & Ratios
PEG Ratio10.65
Price to Book (P/B)5.87
Price to Sales (P/S)2.31
P/FCF Ratio16.85
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit8.51
Enterprise Value/Ebitda13.31
Forecast
1Y Price Target
$258.31Price Target Upside8.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)12.93
Revenue Forecast (FY)$17.06B
Bulls Say, Bears Say
Bulls Say
Accelerating Bookings And RFP FlowImproving net bookings and accelerating RFP flow from pharma and biotech indicate stronger demand that could drive revenue reacceleration and lift future earnings expectations.
AI And Data AssetsIQVIA's extensive healthcare data assets and aggressive investment in AI and analytics can improve drug development insight generation and support higher revenue and margin expansion.
Market Leadership And ScalePosition as the largest global contract research organization provides scale and service breadth that helps secure large client programs and supports steady commercialization-led growth.
Bears Say
Margin Pressure And Mix ShiftMargin headwinds from adverse business mix and historical willingness to discount work may constrain adjusted EBITDA expansion even if revenue recovers.
Technology And Analytics Revenue ShortfallUnderperformance in the technology and analytics segment relative to expectations, combined with lower B2B ratios, could weigh on overall revenue growth and investor sentiment.
Valuation RiskPerception that valuation already reflects expected growth increases downside risk, leaving limited room for meaningful share price appreciation.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings Inc’s price range in the past 12 months?
IQVIA Holdings Inc lowest stock price was $134.65 and its highest was $247.04 in the past 12 months.
What is IQVIA Holdings Inc’s market cap?
IQVIA Holdings Inc’s market cap is $41.09B.
When is IQVIA Holdings Inc’s upcoming earnings report date?
IQVIA Holdings Inc’s upcoming earnings report date is Feb 18, 2026 which is in 31 days.
How were IQVIA Holdings Inc’s earnings last quarter?
IQVIA Holdings Inc released its earnings results on Oct 28, 2025. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.982 by $0.018.
Is IQVIA Holdings Inc overvalued?
According to Wall Street analysts IQVIA Holdings Inc’s price is currently Undervalued.
Does IQVIA Holdings Inc pay dividends?
IQVIA Holdings Inc does not currently pay dividends.
What is IQVIA Holdings Inc’s EPS estimate?
IQVIA Holdings Inc’s EPS estimate is 3.4.
How many shares outstanding does IQVIA Holdings Inc have?
IQVIA Holdings Inc has 170,300,000 shares outstanding.
What happened to IQVIA Holdings Inc’s price movement after its last earnings report?
IQVIA Holdings Inc reported an EPS of $3 in its last earnings report, beating expectations of $2.982. Following the earnings report the stock price went up 0.322%.
Which hedge fund is a major shareholder of IQVIA Holdings Inc?
Currently, no hedge funds are holding shares in IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$258.31 (8.68% Upside)
$258.31 (8.68% Upside)
Blogger Sentiment
Bullish
IQV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.24%
12-Months-Change
Fundamentals
Return on Equity
19.55%
Trailing 12-Months
Asset Growth
5.69%
Trailing 12-Months
Company Description
IQVIA Holdings Inc
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a generally positive sentiment with strong financial performance, record-high free cash flow, and significant growth in net bookings and backlog. However, there were some challenges, particularly in the R&D Solutions segment and delays in mega trials. The company's focus on AI and technology advancements points to optimism for future efficiencies and growth.View all IQV earnings summariesIQV Revenue Breakdown
39.99% Technology & Analytics Solutions
55.35% Research & Development Solutions
4.66% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$258.31
▲(8.68% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
26.53% Mutual Funds
0.45% Other Institutional Investors
48.15% Public Companies and
Individual Investors